TBPH

Theravance Biopharma, Inc. NASDAQ Listed May 16, 2014

Healthcare ·Biotechnology ·KY · theravance.com

$16.94

After hrs $16.94 +0.00%

Mkt Cap $872.3M

52w Low $8.33 67.8% of range 52w High $21.03

50d MA $15.85 200d MA $16.00

P/E (TTM) 8.0x

EV/EBITDA -109.8x

P/B 2.9x

Debt/Equity 0.2x

ROE 20.6%

P/FCF 3.9x

RSI (14) —

ATR (14) —

Beta 0.17

50d MA $15.85

200d MA $16.00

Avg Volume 633.1K

About

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (J…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	0.44	0.06	-86.4%	14.01	+0.4%	+2.3%	+5.3%	+6.4%	+9.1%	+8.4%	—
Nov 10, 2025	AMC	-0.03	0.04	+233.3%	15.08	+3.2%	+22.7%	+17.9%	+19.0%	+15.3%	+19.6%	—
Aug 12, 2025	AMC	-0.14	-0.08	+42.9%	11.92	+0.6%	+4.2%	+8.6%	+10.3%	+14.2%	+12.8%	—
May 8, 2025	AMC	-0.11	-0.17	-54.5%	9.90	-9.3%	-9.3%	-11.1%	-10.0%	-15.1%	-7.7%	—
Feb 26, 2025	AMC	-0.05	-0.05	+0.0%	9.08	+8.8%	+2.1%	+3.0%	+0.8%	+0.2%	+7.0%	—
Nov 12, 2024	AMC	-0.10	-0.06	+40.0%	8.91	+6.3%	+8.6%	+7.4%	+6.8%	+6.5%	+11.3%	—
Aug 5, 2024	AMC	-0.09	-0.13	-44.4%	9.59	-9.8%	-18.4%	-18.4%	-19.9%	-20.1%	-14.1%	—
May 13, 2024	AMC	-0.19	-0.09	+52.6%	9.58	+1.7%	-2.0%	+2.8%	+0.2%	-3.0%	-5.0%	—
Feb 26, 2024	AMC	0.04	0.03	-14.3%	9.23	+0.7%	+5.0%	+1.8%	+2.6%	+2.3%	-1.4%	—
Nov 7, 2023	AMC	-0.10	-0.01	+90.0%	9.73	-3.4%	+5.3%	+3.5%	+3.8%	+4.8%	+5.9%	—
Aug 7, 2023	AMC	-0.16	-0.13	+18.8%	9.83	+3.0%	-0.9%	+3.8%	+1.9%	+1.4%	+2.4%	—
May 8, 2023	AMC	-0.27	-0.24	+11.1%	11.33	+5.7%	+0.4%	+1.2%	-2.1%	-0.3%	-0.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 7	B. Riley Securities	Maintains	Neutral → Neutral	—	$16.10	$16.22	+0.7%	+2.9%	+3.1%	+2.8%	+1.6%	+2.5%
Mar 23	TD Cowen	Maintains	Hold → Hold	—	$14.33	$14.73	+2.8%	+2.9%	+4.0%	+6.7%	+6.0%	+5.2%
Mar 20	BTIG	Maintains	Buy → Buy	—	$14.01	$14.07	+0.4%	+2.3%	+5.3%	+6.4%	+9.1%	+8.4%
Mar 5	Oppenheimer	Downgrade	Outperform → Perform	—	$13.67	$13.50	-1.2%	-0.7%	-0.7%	+2.4%	+2.6%	+1.0%
Mar 4	B. Riley Securities	Downgrade	Buy → Neutral	—	$13.96	$13.37	-4.2%	-2.1%	-2.7%	-2.8%	+0.3%	+0.5%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.96	$13.37	-4.2%	-2.1%	-2.7%	-2.8%	+0.3%	+0.5%
Mar 3	BTIG	Maintains	Buy → Buy	—	$18.95	$14.27	-24.7%	-26.3%	-27.9%	-28.3%	-28.4%	-26.1%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.25	$18.68	+2.4%	+3.8%	-23.5%	-25.1%	-25.6%	-25.6%
Feb 3	BTIG	Maintains	Buy → Buy	—	$19.83	$19.91	+0.4%	+0.8%	+1.3%	-1.3%	+3.3%	-1.7%
Nov 26	BTIG	Maintains	Buy → Buy	—	$18.94	$19.84	+4.8%	+5.4%	+7.2%	+3.5%	-2.7%	-0.3%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.08	$15.57	+3.2%	+22.7%	+17.9%	+19.0%	+15.3%	+19.6%
Jun 27	BTIG	Maintains	Buy → Buy	—	$10.73	$10.95	+2.1%	+4.6%	+2.8%	+1.7%	+3.0%	+3.9%
Feb 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.08	$9.88	+8.8%	+2.1%	+3.0%	+0.8%	+0.2%	+7.0%
Feb 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.86	$8.84	-0.2%	+1.2%	+2.5%	+4.6%	+5.5%	+3.3%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.14	$8.19	+0.6%	-0.2%	+1.2%	+1.6%	+0.9%	-1.6%
Aug 6	TD Cowen	Maintains	Hold → Hold	—	$9.59	$8.65	-9.8%	-18.4%	-18.4%	-19.9%	-20.1%	-14.1%
Aug 6	Leerink Partners	Downgrade	Outperform → Market Perform	—	$9.59	$8.65	-9.8%	-18.4%	-18.4%	-19.9%	-20.1%	-14.1%
Aug 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.59	$8.65	-9.8%	-18.4%	-18.4%	-19.9%	-20.1%	-14.1%
May 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.41	$8.33	-1.0%	-1.4%	+1.0%	+2.5%	+1.4%	+2.6%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.58	$9.74	+1.7%	-2.0%	+2.8%	+0.2%	-3.0%	-5.0%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.83	$10.12	+3.0%	-0.9%	+3.8%	+1.9%	+1.4%	+2.4%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.33	$11.98	+5.7%	+0.4%	+1.2%	-2.1%	-0.3%	-0.6%
Nov 17	SVB Leerink	Maintains	Outperform → Outperform	—	$11.22	$11.30	+0.7%	+1.1%	-3.3%	-7.4%	-5.4%	-8.5%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.05	$10.36	+3.1%	+3.1%	+8.5%	+12.3%	+12.1%	+12.3%
Jul 25	Morgan Stanley	Maintains	Underweight → Underweight	—	$9.69	$9.59	-1.0%	-4.6%	-7.5%	-7.7%	-8.6%	-9.3%
Mar 2	Morgan Stanley	Maintains	Underweight → Underweight	—	$10.49	$10.63	+1.3%	-2.3%	-5.5%	-8.4%	-7.7%	-6.7%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.11	$9.46	+3.8%	+9.0%	+12.4%	+10.5%	+15.1%	+12.5%
Nov 5	JP Morgan	Upgrade	Underweight → Neutral	—	$8.50	$8.95	+5.3%	+6.5%	+5.3%	+2.0%	+0.5%	-1.6%
Sep 16	SVB Leerink	Maintains	Outperform → Outperform	—	$6.77	$6.89	+1.8%	+1.3%	+5.0%	+1.6%	+4.9%	+6.6%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.77	$6.89	+1.8%	+1.3%	+5.0%	+1.6%	+4.9%	+6.6%
Sep 16	Morgan Stanley	Maintains	Underweight → Underweight	—	$6.77	$6.89	+1.8%	+1.3%	+5.0%	+1.6%	+4.9%	+6.6%
Aug 25	Morgan Stanley	Downgrade	Overweight → Underweight	—	$9.24	$9.21	-0.3%	-5.8%	-10.9%	-10.9%	-9.1%	-10.2%
Aug 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.17	$10.27	-27.5%	-34.8%	-38.6%	-41.9%	-41.9%	-40.7%
Aug 24	SVB Leerink	Maintains	Outperform → Outperform	—	$14.17	$10.27	-27.5%	-34.8%	-38.6%	-41.9%	-41.9%	-40.7%
Aug 24	Cowen & Co.	Downgrade	Outperform → Market Perform	—	$14.17	$10.27	-27.5%	-34.8%	-38.6%	-41.9%	-41.9%	-40.7%
Aug 24	Needham	Maintains	Buy → Buy	—	$14.17	$10.27	-27.5%	-34.8%	-38.6%	-41.9%	-41.9%	-40.7%
Aug 4	SVB Leerink	Maintains	Outperform → Outperform	—	$13.63	$14.13	+3.7%	-4.6%	-1.3%	-4.6%	-4.6%	-0.8%
Jul 16	Morgan Stanley	Maintains	Overweight → Overweight	—	$13.62	$13.70	+0.6%	-2.6%	-1.8%	+3.7%	+1.8%	+1.0%
Jun 28	SVB Leerink	Maintains	Outperform → Outperform	—	$15.60	$15.80	+1.3%	+0.8%	-3.8%	-6.9%	-7.6%	-7.9%
May 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$18.87	$19.02	+0.8%	-0.8%	-0.8%	-2.4%	-4.2%	-6.7%
May 5	Needham	Maintains	Buy → Buy	—	$19.88	$19.85	-0.2%	-1.6%	-2.5%	-0.7%	-3.5%	-6.7%
May 5	SVB Leerink	Maintains	Outperform → Outperform	—	$19.88	$19.85	-0.2%	-1.6%	-2.5%	-0.7%	-3.5%	-6.7%
Apr 1	SVB Leerink	Maintains	Outperform → Outperform	—	$20.41	$20.47	+0.3%	-1.4%	+0.7%	+1.7%	+5.6%	+6.7%
Mar 1	Morgan Stanley	Maintains	Overweight → Overweight	—	$16.57	$16.77	+1.2%	+5.5%	+11.0%	+14.2%	+13.2%	+17.4%
Feb 24	SVB Leerink	Maintains	Outperform → Outperform	—	$17.65	$19.14	+8.4%	-0.9%	-1.9%	-6.1%	-1.0%	+4.2%
Dec 16	Morgan Stanley	Maintains	Overweight → Overweight	—	$19.74	$19.87	+0.7%	-3.5%	-2.6%	-1.4%	-3.7%	-3.4%
Nov 6	SVB Leerink	Maintains	Outperform → Outperform	—	$19.48	$18.73	-3.9%	-13.8%	-8.3%	-4.1%	-5.8%	-10.4%
Oct 14	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$17.28	$19.40	+12.3%	+9.6%	+6.5%	+7.2%	+8.2%	+6.5%
Aug 10	Piper Sandler	Maintains	Overweight → Overweight	—	$17.96	$18.04	+0.4%	-2.3%	-4.5%	-6.4%	-5.8%	-7.0%
Aug 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$17.96	$18.04	+0.4%	-2.3%	-4.5%	-6.4%	-5.8%	-7.0%

Recent Filings

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

Resolution of all Hatch-Waxman litigation for YUPELRI removes legal uncertainty and allows the company to fully capitalize on this respiratory drug's market potential without ongoing patent disputes.

Mar 30

8-K

Unknown — 8-K Filing

Theravance Biopharma's full-year 2025 results indicate operational progress; investors should monitor revenue trends and pipeline developments to assess whether the biotech firm can achieve profitability and justify its current valuation.

Mar 19

8-K · 7.01 ! Medium

Theravance Biopharma, Inc. -- 8-K 7.01: Regulation FD Disclosure

Theravance disclosed material non-public information to select parties, requiring broad disclosure to maintain fair access, which could signal pending news affecting stock valuation.

Mar 3

Data updated apr 27, 2026 4:06am · Source: massive.com